gptkbp:instanceOf
|
peptide
immunosuppressant drug
|
gptkbp:approvedBy
|
liver transplant
bone marrow transplant
kidney transplant
heart transplant
lung transplant
1983 (US)
|
gptkbp:ATCCode
|
L04AD01
|
gptkbp:bioavailability
|
30% (oral)
|
gptkbp:brand
|
gptkb:Gengraf
gptkb:Sandimmune
gptkb:Neoral
|
gptkbp:CASNumber
|
79217-60-0
|
gptkbp:chemicalFormula
|
cyclic undecapeptide
|
gptkbp:contraindication
|
uncontrolled hypertension
malignancy
hypersensitivity to ciclosporin
|
gptkbp:discoveredBy
|
gptkb:Jean-François_Borel
|
gptkbp:discoveredIn
|
1971
|
gptkbp:eliminationHalfLife
|
8.4 hours
|
gptkbp:excretion
|
bile
|
gptkbp:hasMolecularFormula
|
C62H111N11O12
|
https://www.w3.org/2000/01/rdf-schema#label
|
ciclosporin
|
gptkbp:interactsWith
|
gptkb:rifampicin
gptkb:milk
gptkb:phenytoin
gptkb:ketoconazole
gptkb:St._John's_wort
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
immunosuppressant
|
gptkbp:metabolism
|
gptkb:CYP3A4
liver
|
gptkbp:molecularWeight
|
1202.61 g/mol
|
gptkbp:origin
|
Tolypocladium inflatum (fungus)
|
gptkbp:patent
|
1970
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:proteinBinding
|
90%
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
gptkbp:sideEffect
|
hypertension
nephrotoxicity
hirsutism
gingival hyperplasia
|
gptkbp:synonym
|
gptkb:cyclosporine
ciclosporin A
|
gptkbp:usedFor
|
prevention of organ transplant rejection
treatment of psoriasis
treatment of rheumatoid arthritis
treatment of atopic dermatitis
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
gptkbp:bfsParent
|
gptkb:L04AB01
gptkb:Ikervis
|
gptkbp:bfsLayer
|
7
|